Bank of America Corp allocates approximately $250 million annually to provide GLP-1 obesity medications to its employees, a figure that represents about 13% of its total $2 billion yearly healthcare expenditure. CEO Brian Moynihan described the spending as "a good investment" in workforce health and productivity, noting that the cost has risen from zero four or five years ago. The bank combines medication coverage with health coaching to support weight management and lifestyle changes, citing evidence that these drugs may reduce cardiovascular event risks.

Healthcare Spending Breakdown

The rapid increase in GLP-1 coverage reflects broader trends in corporate health benefits, where employers are grappling with rising drug costs. Bank of America’s strategy involves leveraging its size to negotiate better terms with suppliers.

Moynihan acknowledged that the company may not fully recoup long-term health benefits if employees leave, but maintains the coverage as part of its commitment to employee benefits. The bank continues to offer this support while negotiating lower prices with drugmakers and pharmacy benefit managers (PBMs).

Industry Context and Employer Trends

A June survey by the International Foundation of Employee Benefit Plans (IFEBP) of nearly 300 U.S. employer health plans found that 36% cover GLP-1 drugs such as Novo Nordisk A/S’s Ozempic and Wegovy for both diabetes and weight loss, unchanged from 2025. Meanwhile, 60% provide coverage for diabetes only, up from 55% a year earlier. About 45% also cover the drugs for other approved conditions, including heart disease and obstructive sleep apnea.

The IFEBP identified cost as the primary factor shaping employer decisions, with GLP-1 drugs’ share of annual claims rising from 6.9% in 2023 to 11.4% in 2026. Eli Lilly and Co. and Novo Nordisk are expanding efforts to increase employer insurance coverage, as out-of-pocket costs remain high for many patients. In March, Eli Lilly introduced a program allowing employers to offer Zepbound at a discounted net price of $449 per month.

What the Numbers Show

The financial data highlights a significant shift in corporate healthcare allocation, with GLP-1 medications now commanding a substantial portion of total health budgets. While Bank of America’s $250 million spend is specific, the industry-wide rise in claims share—from 6.9% to 11.4% in three years—indicates systemic pressure on employer-sponsored plans. This trend underscores the growing dependence of pharmaceutical sectors on obesity treatments, which now account for 25% of projected late-stage pipeline sales according to a Deloitte report, raising concerns about a potential "bubble effect" in R&D returns.

Bank of America has exited Chicago's plan to sell overdue parking debt, altering the city's approach to managing delinquent accounts. The withdrawal marks a shift in the financial arrangement aimed at addressing outstanding liabilities. The decision underscores the complexities involved in monetizing municipal debt.

The proposed sale was intended to convert overdue parking fines into a more liquid asset for the city. Bank of America's exit follows a review of the plan's structure and potential risks. The city had sought to leverage the debt to improve cash flow and reduce administrative burdens associated with collections.

Chicago's parking debt has been a persistent challenge, with significant amounts remaining unpaid over time. The sale plan was part of broader efforts to address fiscal pressures. The withdrawal by Bank of America may prompt the city to explore alternative strategies for debt recovery.

The table below outlines key details of the proposed arrangement:

The city has not yet announced a replacement partner or revised timeline for the debt sale. The focus remains on resolving the outstanding parking liabilities while minimizing financial impact. Stakeholders will monitor for further developments on Chicago's debt management strategy.